Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Millan

Showing results (191-200 of 224) with videos related to

Pageof 23
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|May 17, 2003
The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathwaysM J Millan, A Gobert, F Lejeune, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|January 1, 1987
A model of chronic pain in the rat: functional correlates of alterations in the activity of opioid systemsM J Millan, A Członkowski, C W Pilcher, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|June 1, 1997
Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapyA Newman-Tancredi, C Conte, C Chaput, et al.
Neuropharmacology|August 26, 1998
Interaction of the anxiogenic agent, RS-30199, with 5-HT1A receptors: modulation of sexual activity in the male ratM Spedding, A Newman-Tancredi, M J Millan, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1995
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathwaysA Gobert, J M Rivet, V Audinot, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1997
S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activityM J Millan, A Newman-Tancredi, J M Rivet, et al.
The European Journal of Neuroscience|December 14, 1999
Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the ratM J Millan, M Brocco, A Gobert, et al.
Journal of Medicinal Chemistry|September 29, 1995
Characterization of potent and selective antagonists at postsynaptic 5-HT1A receptors in a series of N4-substituted arylpiperazinesJ L Peglion, H Canton, K Bervoets, et al.
European Journal of Pharmacology|August 1, 1994
S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in ratsM J Millan, V Audinot, J M Rivet, et al.
Psychopharmacology|November 5, 2013
CRF1 receptor antagonists do not reverse pharmacological disruption of prepulse inhibition in rodentsT N Douma, M J Millan, D Boulay, et al.
Pageof 23

Showing results (191-200 of 224) with videos related to

Sort By:
Pageof 23
The Journal of Pharmacology and Experimental Therapeutics|May 17, 2003
The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathwaysM J Millan, A Gobert, F Lejeune, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|January 1, 1987
A model of chronic pain in the rat: functional correlates of alterations in the activity of opioid systemsM J Millan, A Członkowski, C W Pilcher, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|June 1, 1997
Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapyA Newman-Tancredi, C Conte, C Chaput, et al.
Neuropharmacology|August 26, 1998
Interaction of the anxiogenic agent, RS-30199, with 5-HT1A receptors: modulation of sexual activity in the male ratM Spedding, A Newman-Tancredi, M J Millan, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1995
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathwaysA Gobert, J M Rivet, V Audinot, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1997
S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activityM J Millan, A Newman-Tancredi, J M Rivet, et al.
The European Journal of Neuroscience|December 14, 1999
Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the ratM J Millan, M Brocco, A Gobert, et al.
Journal of Medicinal Chemistry|September 29, 1995
Characterization of potent and selective antagonists at postsynaptic 5-HT1A receptors in a series of N4-substituted arylpiperazinesJ L Peglion, H Canton, K Bervoets, et al.
European Journal of Pharmacology|August 1, 1994
S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in ratsM J Millan, V Audinot, J M Rivet, et al.
Psychopharmacology|November 5, 2013
CRF1 receptor antagonists do not reverse pharmacological disruption of prepulse inhibition in rodentsT N Douma, M J Millan, D Boulay, et al.
Pageof 23